Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
26-28 February, 2026
euroPLX 90 LisboneuroPLX 90 Lisbon
Not Confirmed
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Not Confirmed
Not Confirmed
02-03 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
ASCO GU
Not Confirmed
Contact SupplierASCO GU
Industry Trade Show
Not Confirmed
26-28 February, 2026
euroPLX 90 LisboneuroPLX 90 Lisbon
Industry Trade Show
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Industry Trade Show
Not Confirmed
02-03 March, 2026
Digital content
NEWS #PharmaBuzz
10 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260210569136/en/Enanta-Pharmaceuticals-to-Present-Preclinical-Data-for-EDP-978-its-KIT-Inhibitor-in-Development-for-the-Treatment-of-Type-2-Immune-Diseases-at-the-2026-AAAAI-Annual-Meeting
09 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260209293558/en/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-First-Quarter-Ended-December-31-2025
08 Jan 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-01-08/enanta-pharmaceuticals-provides-update-on-its-research-and-development-programs-and-2026-outlook
05 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260105272702/en/Enanta-Pharmaceuticals-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference
17 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251117823831/en/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Fourth-Quarter-and-Year-Ended-September-30-2025
04 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251104405023/en/Enanta-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences
Drugs in Development
Details:
In the public offering, small molecule drugs for viral infections will be supported, advancing research in this critical area.
Lead Product(s): EDP-514
Therapeutic Area: Infections and Infectious Diseases Brand Name: EDP-514
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $74.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2025
Lead Product(s) : EDP-514
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $74.7 million
Deal Type : Public Offering
Enanta Closes Upsized Public Offering with Full Underwriters' Option Exercise
Details : In the public offering, small molecule drugs for viral infections will be supported, advancing research in this critical area.
Product Name : EDP-514
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 02, 2025
Details:
The net proceeds will be used to advance company's product candidates, including EDP-514, a novel core inhibitor.
Lead Product(s): EDP-514,Itraconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: EDP-514
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: $65.0 million
Deal Type: Public Offering September 30, 2025
Lead Product(s) : EDP-514,Itraconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Details : The net proceeds will be used to advance company's product candidates, including EDP-514, a novel core inhibitor.
Product Name : EDP-514
Product Type : Miscellaneous
Upfront Cash : $65.0 million
September 30, 2025
Details:
The net proceeds will be used to advance company's product candidates, including EDP-514, a novel core inhibitor.
Lead Product(s): EDP-514
Therapeutic Area: Infections and Infectious Diseases Brand Name: EDP-514
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Undisclosed Upfront Cash: $50.0 million
Deal Type: Public Offering September 30, 2025
Lead Product(s) : EDP-514
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Undisclosed
Deal Type : Public Offering
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Details : The net proceeds will be used to advance company's product candidates, including EDP-514, a novel core inhibitor.
Product Name : EDP-514
Product Type : Miscellaneous
Upfront Cash : $50.0 million
September 30, 2025
Details:
Mavyret (glecaprevir, pibrentasvir) inhibits P-glycoprotein, approved as the only eight-week treatment for three years and older with HCV infection without cirrhosis or with compensated cirrhosis.
Lead Product(s): Glecaprevir,Pibrentasvir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mavyret
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: AbbVie Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 11, 2025
Lead Product(s) : Glecaprevir,Pibrentasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Expands MAVYRET® Use for Hepatitis C for Enanta and AbbVie
Details : Mavyret (glecaprevir, pibrentasvir) inhibits P-glycoprotein, approved as the only eight-week treatment for three years and older with HCV infection without cirrhosis or with compensated cirrhosis.
Product Name : Mavyret
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 11, 2025
Details:
EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Lead Product(s): EDP-323,Midazolam,Caffeine,Rosuvastatin Calcium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2025
Lead Product(s) : EDP-323,Midazolam,Caffeine,Rosuvastatin Calcium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2025
Details:
EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Lead Product(s): EDP-323,Itraconazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2025
Lead Product(s) : EDP-323,Itraconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2025
Details:
EDP-938 (zelicapavir) is a RSV N-protein inhibitor, small molecule drug candidate. It is being evaluated for the treatment of respiratory syncytial virus infection.
Lead Product(s): Zelicapavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Enanta Reports Positive Phase 2 Results for Zelicapavir in Respiratory Syncytial Virus
Details : EDP-938 (zelicapavir) is a RSV N-protein inhibitor, small molecule drug candidate. It is being evaluated for the treatment of respiratory syncytial virus infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024
Details:
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV).
Lead Product(s): EDP-323
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2024
Lead Product(s) : EDP-323
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Enanta Reports Positive Topline Results for EDP-323 in RSV Human Challenge Study
Details : Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2024
Details:
Zelicapavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Lead Product(s): Zelicapavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
Details : Zelicapavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Details:
EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Lead Product(s): EDP-323
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: hVIVO
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 14, 2023
Lead Product(s) : EDP-323
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : hVIVO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDP-323 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
